What the tablet’s documents include
Venous clots do not appear in the adverse-reaction sections for Rybelsus® in any of the three regions [1][2][3]. What does appear is an interaction note about warfarin and related blood thinners, and the regions word it differently.
| Document | What it says | Practical point |
|---|---|---|
| US Prescribing Information, sections 6 and 12.3 [1] | No venous clot listed; no clinically significant change in S- or R-warfarin levels with semaglutide tablets | No specific INR instruction |
| EU summary of product characteristics, section 4.5 [2] | Warfarin levels and INR not affected in a clinically relevant way, but lower INR reported with acenocoumarol | Frequent INR monitoring when semaglutide is started |
| EU package leaflet, section 2 [2] | Tell your doctor if you take warfarin or similar oral anticoagulants | You may need frequent blood clotting tests |
| Canadian Product Monograph, section 9.4 [3] | Same acenocoumarol reports and INR advice | Frequent INR monitoring at the start |
If you already take a blood thinner
Many people with type 2 diabetes and heart disease take an anticoagulant, so this is the part of the topic with the most direct label wording. A manufacturer-run crossover study gave healthy volunteers warfarin alone, then with SNAC alone, then with oral semaglutide at steady state; neither changed the amount of warfarin in the blood, and SNAC alone did not alter it either [4]. The US label reports the same [1].
Europe and Canada still advise frequent INR checks when semaglutide is started in people on warfarin or other coumarins, because cases of decreased INR were reported with acenocoumarol, a related blood thinner [2][3]. The EU leaflet puts it plainly: you may need frequent blood tests to check how quickly your blood clots [2]. How often to test is for your anticoagulation clinic or prescriber to decide.
Timing matters too. Rybelsus® is swallowed alone on an empty stomach with up to 120 mL of water, and other oral medicines wait at least 30 minutes [1][3]. Canada notes that taking five other tablets at the same moment cut semaglutide exposure by about a third [3], so a morning blood thinner fits after that gap.
What trial analyses and reports show
Two 2025 meta-analyses of randomised GLP-1 trials reached different conclusions. One pooled 39 trials with 70,499 participants and found a non-significant upward trend in venous thromboembolism overall (odds ratio 1.19) but a higher risk of DVT (odds ratio 1.64), most marked in trials lasting longer than 18 months and in cardiovascular outcome trials, with no change in pulmonary embolism [5]. The other pooled 27 placebo-controlled trials with 84,003 participants and found no significant difference in overall clot risk (risk ratio 0.70) and a lower risk of pulmonary embolism (risk ratio 0.60) [6]. Neither reported results for the tablet on its own.
For semaglutide tablets specifically, a 2024 analysis of US FDA reports from 2019 to 2023 found 53 reports in the vascular category, fewer than expected compared with other medicines (reporting odds ratio 0.49) [7]. A 2026 case report describes a 16-year-old with overweight and long periods of sitting who developed a DVT in the thigh and knee veins within two weeks of starting Rybelsus® 7 mg for weight loss without medical supervision; clotting-disorder tests were negative and he improved on anticoagulants [8]. A single case cannot show that the tablet caused the clot, but the authors note it was the first limb DVT reported with oral semaglutide.
Possible links, and how firm they are
- Supported by the label: vomiting and diarrhoea can cause dehydration, which section 5.5 links to kidney injury [1]. The case-report authors suggested that thicker, more concentrated blood after stomach side effects might contribute to clotting [8]; that link is proposed, not measured.
- Proposed in the literature: effects of GLP-1 medicines on coagulation or the lining of blood vessels, mentioned as possibilities in the same report [8].
- General medical knowledge: slow blood flow from sitting or bed rest, vein injury from surgery, and oestrogen are well-established causes of venous clots [9][11].
Risk factors that matter for everyone
The CDC notes that the chance of a clot rises with each additional risk factor a person has [9]. Its list, together with MedlinePlus, includes:
- Major surgery, especially of the abdomen, pelvis, hip or legs, fractures and severe muscle injury.
- Bed rest, a leg in a cast, or sitting for a long time, for example on long car or plane journeys.
- Oestrogen from combined contraceptives or hormone therapy, pregnancy and the three months after birth.
- Heart or lung disease, cancer and its treatment, inflammatory bowel disease, smoking, older age, obesity, and a personal or family history of clots [9][11].
What official sources suggest
MedlinePlus advises moving your legs often on long trips and in other situations where you sit or lie still for a long time, taking any blood thinner your provider prescribes, and not smoking [11]. Cleveland Clinic adds that a clot can form when you are not moving for more than four hours during travel [10].
Surgery is both a clot risk and a moment when the Rybelsus® label asks you to speak up: the tablets slow stomach emptying, and you should tell the team before any procedure with general anaesthesia or deep sedation [1]. Mention any history of clots and any blood thinners in the same conversation.
Rybelsus® and Ozempic® are registered trademarks of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.
When to get help
The signs and contact information below come from this article’s sourced guidance.
Emergency
- Chest pain, sudden shortness of breath, coughing up blood, lightheadedness or fainting
Contact: Emergency services
- Swelling, pain, warmth or redness in one leg or arm
Contact: Your provider right away, or the emergency room; do not wait
Cleveland Clinic [10]
- On a blood thinner: heavy bleeding, or bright red blood in vomit or stool
Contact: Emergency care
Cleveland Clinic [10]